Latest News
Regulus Therapeutics Inc. (RGLS) Regulus Therapeutics Inc (RGLS) presents an intriguing investment opportunity, as highlighted by the latest stock analysis. According to forecasts from three analysts, the average target price for Regulus Therapeutics Inc is set at USD 9.14 over the next 12 months. This target suggests a significant upside...
Group behind one of biggest Canadian biotech takeovers unveils latest addition to Vancouver’s teeming life sciences sector
A California-based biotech company is kicking the week off with a bang as shares are already on the move so far during Monday’s premarket hours. This can likely be attributed to the fact that the company announced that their potential kidney disease drug (RGLS8429) was “well-tolerated with no safety concerns.”Traders...
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
/PRNewswire/ -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting...
Regulus Therapeutics Strengthens Research & Development Leadership
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...